Aimmune Therapeutics

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Shares of Aimmune Therapeutics Inc. AIMT, -11.03% jumped 9% after the company announced a $200 million investment from Nestlé Health Science on the heels of a Food and Drug Administration approval of Aimmune's peanut allergy treatment.

Aimmune's stock is up on Nestlé investment

The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies.

What Aimmune's Peanut Allergy Drug Approval Means for the Rest of the Pipeline

Biohaven Pharmaceutical Hld

Of the ten most anticipated drug launches expected this year, two will have the biggest impact on the top line—and possibly the share price--of the companies introducing them.

Analysts Forecast Huge Upsides for Aimmune, Biohaven

The first approved drug for any food allergy may be the first of several from Aimmune Therapeutics.

FDA Approves First Drug for Peanut Allergy

Aimmune Therapeutics Inc (NASDAQ: AIMT) announced late Friday that it received FDA approval for Palforzia, its oral immunotherapy to treat peanut allergy.

Aimmune Analysts Bullish On Strong Uptake Of Peanut Allergy Drug Palforzia

Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.

Aimmune's Palforzia Wins FDA Approval for Peanut Allergy

Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares jumped early on Monday after the U.S. Food and Drug Administration (FDA) announced late Friday a critical approval for the firm’s peanut allergy treatment.

FDA Approves First-Ever Peanut Allergy Treatment

Biotech company Aimmune Therapeutics gained Food and Drug Administration approval for a first-of-its-kind peanut allergy treatment, Palforzia, sending AIMT stock rocketing on Monday.
The post Aimmune Stock Flies On First-Of-Its-Kind Peanut Allergy Approval appeared first on Investor's Business Daily.

Aimmune Stock Flies On First-Of-Its-Kind Peanut Allergy Approval

The US has approved a drug which aims to eliminate peanut allergies in children aged four to 17.

First drug to treat peanut allergies in children approved in US

Shares of biopharma Aimmune Therapeutics Inc (NASDAQ: AIMT) advanced strongly in after-hours trading Friday following a positive FDA verdict for Aimunne's peanut allergy drug.

Aimmune's 'First-Of-Its-Kind' Peanut Allergy Drug Receives FDA Approval

Shares of Aimmune Therapeutics Inc. AIMT, -2.91% rose more than 12% in the extended session Friday after the Brisbane, Calif.

Aimmune Therapeutics stock rallies after FDA approves peanut-allergy drug

AIMT Remains Undervalued Before FDA Decision On Palforzia

Investors need to pay close attention to Aimmune Therapeutics (AIMT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?

An upcoming FDA decision on Aimmune’s first drug could set the tone for the rest of its pipeline.

Why the FDA's Decision on Aimmune's Peanut Allergy Drug Is Crucial for the Company -- and Patients

Aimmune's PDUFA Jitters, And Other News: The Good, Bad And Ugly Of Biopharma

Disney

Freeport-McMoRan

Hercules Capital

PennyMac Financial Services

2019 is all but in-the-bag and at this point, and what a year it was for stocks.

5 Great Stocks for 2020

AIMT has the potential to help peanut allergy sufferers in a big way in 2020

Best Stocks for 2020: Aimmune’s Allergy Solutions Position It for Huge Success

Aimmune: High Probability Events Approaching

Epizyme

Esperion Therapeutics

Horizon Pharma

With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.

4 Healthcare Stocks With FDA Approvals on the Horizon

First Majestic Silver

Antero Midstream Partners

Amarin Corporation Plc

Exelixis

Intercept Pharma

Innovative Industrial Properties

Lovesac Company

Livongo Health Inc

Meet Group

Ping Identity Holding Corp

Pinterest

Redfin

Stitch Fix

StoneCo

Teva Pharmaceutical

Trupanion

Big gains could be just a click of the buy button away.

20 Stocks That Could Double Your Money in 2020

Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q3 2019 Results - Earnings Call Transcript

This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.

Use Aimmune Therapeutics to Profit off the Rush Into Biotech

A survey of allergists suggests Palforzia's launch could be more successful than expected.

Here's Why Aimmune Therapeutics Stock Jumped on Wednesday

An FDA advisory panel recommended 7-2 that Palforzia should be approved for the treatment of peanut allergy.

Aimmune: FDA Panel Nod Pushes Peanut Allergy Treatment One Step Closer To Potential Approval

Aimmune Therapeutics Inc (NASDAQ: AIMT)'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA.

News for Aimmune Therapeutics Stock (AIMT)